PropertyValue
?:abstract
  • The SARS-CoV-2 virus has emerged and rapidly evolved into a current global pandemic. Although bacterial and fungal coinfections have been associated with COVID-19, little is known about parasitic infection. We report a case of a COVID-19 patient who developed disseminated strongyloidiasis following treatment with high-dose corticosteroids and tocilizumab. Screening for Strongyloides infection should be pursued in individuals with COVID-19 who originate from endemic regions before initiating immunosuppressive therapy.
?:creator
?:doi
  • 10.4269/ajtmh.20-0699
?:doi
?:journal
  • Am_J_Trop_Med_Hyg
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/db9617c1d8243940499433c1ae29f8cb7fa275d2.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7543803.xml.json
?:pmcid
?:pmid
?:pmid
  • 32830642.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19
?:type
?:year
  • 2020-08-14

Metadata

Anon_0  
expand all